Replies to post #44981 on Biotech Values

[jellybean]

<<<that you could have 10,000 patients in this trial >>>

but they don't. the number of patients in the Provenge trial is exactly the problem -- fewer than 250. You often post about the statisticians who work with you...I can't believe that they are comfortable with the numbers from the Provenge trials.

Subset analysis of the control arm of provenge is pure and simple bad science.

Yes, there is a suggestion of efficacy with Provenge, but given that the MOA does not stand up under close scrutiny, and given the small numbers of patients enrolled in the trials, any respectable scientist would be cautious about saying the treatment works.